NBI-1070770
NBI-1070770-MDD2029
Phase 2 small_molecule completed
Quick answer
NBI-1070770 for Major Depressive Disorder is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Major Depressive Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed